Form 10-Q Opexa Therapeutics, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Opexa Therapeutics (OPXA) Tops Q1 EPS by 4c
May 12, 2016 4:57 PM EDTOpexa Therapeutics (NASDAQ: OPXA) reported Q1 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $726.3 thousand versus the consensus estimate of $400 thousand.
Financial Guidance
Based on the current activities of the Company and projected... More
